In the third installment of RSV Roundtable, our panel discusses the impact nirsevimab has had this RSV season.
Welcome to the third episode of our 5-episode series; respiratory syncytial virus (RSV) Roundtable, a collaborative project from Contemporary Pediatrics, Contagion, and Contemporary OB/GYN.
This series discusses several aspects of RSV including incidence rates, vaccines, and immunizations.
In this episode, our panel highlights what type of impact nirsevimab (Beyfortus; Sanofi, AstraZeneca) has made this RSV season. In this discussion, the monoclonal antibody's availability and rollout process is also in the spotlight amid a plan to roll out some 230,000 additional doses in January 2024.
Our panel of clinicians includes:
Click here for the first episode of RSV Roundtable.
Click here for the second episode of RSV Roundtable.
This series will release a new episode every Friday through January 5, 2024.
For a full list of already-published episodes, click here.
Thanks for watching RSV Roundtable.
This article was initially published by our sister publication Contemporary Pediatrics.
RSV Roundtable: Disease education, vaccine hesitancy, and awareness
December 15th 2023In the second installment of RSV Roundtable, our panel explains how they are educating patients and parents when it comes to RSV, vaccines and preventive measures, and limited treatment availability.
Read More